Review Article

Effectiveness of the Clinical Pathway in the Management of Congestive Heart Failure

Authors: Aparna Ranjan, MD, Leena Tarigopula, MD, Rakesh K. Srivastava, PhD, Olugbenga O. Obasanjo, MD, PhD, Eugene Obah, MD

Abstract

Background: The prevalence of congestive heart failure (CHF) in the United States is approximately 4 million, with associated annual health care expenditures exceeding $8 billion. Clinical pathways for CHF have been developed, but they have not been rigorously evaluated regarding efficacy and improvement in the quality of care. We sought to evaluate the effect of a CHF clinical pathway on hospital charges, length of stay, and use of angiotensin-converting enzyme (ACE) inhibitors in patients with CHF in a retrospective cohort study.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–115.
 
2. Agency for Health Care Policy and Research (AHCPR). Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction(AHCPR Publication No. 94-0612). Rockville, MD, AHCPR, 1994.
 
3. Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1995; 26: 1376–1398.
 
4. Graves EJ. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1990. Vital Health Stat 13 1992; 113: 1–225.
 
5. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973–1986: Evidence for increasing population prevalence. Arch Intern Med 1990; 150: 769–773.
 
6. Agency for Health Care Policy and Research (AHCPR). Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction(AHCPR Publication No. 94-0613). Rockville, MD, AHCPR, 1994.
 
7. Graves EJ. National Hospital Discharge Survey: Annual summary, 1993. Vital Health Stat 13 1995; 121: 1–63.
 
8. Levit KR, Lazenby HC, Cowan CA, Letsch SW. National health expenditures, 1990. Health Care Financ Rev 1991; 13: 29–54.
 
9. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994; 13: S107–S112.
 
10. Venner GH, Seelbinder JS. Team management of congestive heart failure across the continuum. J Cardiovasc Nurs 1996; 10: 71–84.
 
11. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460–2464.
 
12. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450–1456.